KALEIDO BIOSCIENCES INC - KLDO STOCK NEWS

Kaleido Biosciences (Nasdaq: KLDO) has announced the extension and expansion of its collaboration with Janssen Biotech to explore Microbiome Metabolic Therapies (MMT™) aimed at preventing childhood-onset atopic, immune, and metabolic conditions. The collaboration has successfully identified several potential MMTs that promote beneficial gut microbiome microbes. Janssen will fund the expanded research scope. Kaleido's platform is designed to efficiently develop MMT candidates for clinical studies, highlighting its focus on supporting infant immune system development.

Kaleido Biosciences, a clinical-stage biotech company focused on treating inflammatory conditions, announced that CEO Dan Menichella will participate in a fireside chat at the Piper Sandler 33rd Annual Virtual Healthcare Conference. The presentation will be available on-demand starting at 10:00 AM ET on November 22, 2021. Investors can access the webcast in the Investors & Media section of Kaleido's website, with an archived replay available for 90 days post-event. The company aims to restore gut-immune homeostasis through its proprietary Microbiome Metabolic Therapies.

Kaleido Biosciences (Nasdaq: KLDO) announced the appointment of Alison Long, M.B.B.Ch., Ph.D., as Chief Medical Officer, effective December 15, 2021. Dr. Long will lead the company's clinical programs, including the development of KB295 for ulcerative colitis and KB109 for chronic obstructive pulmonary disease. Her extensive experience in drug development, including five successful regulatory approvals, is expected to enhance Kaleido's pipeline advancement towards Phase 2 clinical trials next year, focusing on Microbiome Metabolic Therapies.

Kaleido Biosciences (Nasdaq: KLDO) announced positive results from its Phase 1 study of KB295 for mild-to-moderate ulcerative colitis, achieving its primary goal of safety and tolerability. The study indicated significant reductions in biomarkers linked to disease activity. The company also plans to initiate Phase 2 trials for KB295 in ulcerative colitis and KB109 in COPD by mid-2022. For Q3 2021, Kaleido reported a net loss of $23.1 million ($0.54 per share) and increased R&D expenses of $17.4 million, partially offset by a decrease in G&A expenses to $5.1 million.

Kaleido Biosciences (Nasdaq: KLDO) will have CEO Dan Menichella present a company overview at the Jefferies Virtual Next Generation IBD Therapeutics Summit on October 19, 2021, at 1:45 PM ET. This presentation will focus on the company's innovative approach to treating inflammatory diseases through microbiome modulation. Investors can access the live webcast and an archived replay for 30 days on the company’s website. Kaleido leverages a proprietary platform for discovering Microbiome Metabolic Therapies aimed at addressing unmet patient needs in various diseases.

Kaleido Biosciences, Inc. (Nasdaq: KLDO) has announced positive topline data from its clinical study of KB295, a Microbiome Metabolic Therapy, in mild-to-moderate ulcerative colitis (UC). The primary endpoint of safety and tolerability was met, with no serious adverse events reported. Key inflammatory biomarkers, including fecal calprotectin and fecal lactoferrin, showed significant reductions—69% median decrease in fecal calprotectin for evaluable subjects. The company plans to initiate a Phase 2 study for KB295 in the first half of 2022, supported by these promising results.

Kaleido Biosciences plans to advance its Microbiome Metabolic Therapies (MMT™), KB295 and KB109, into Phase 2 studies targeting ulcerative colitis (UC) and chronic obstructive pulmonary disease (COPD). A virtual R&D Presentation is scheduled for October 5, 2021, featuring updates on corporate strategy, data from a study assessing KB295 for mild-to-moderate UC, and supportive preclinical findings for KB109. Key experts will present, including Dr. Bruce Sands and Dr. Ruth Tal-Singer.

Kaleido Biosciences (Nasdaq: KLDO) announced CEO Dan Menichella will participate in a fireside chat at the Morgan Stanley 19th Annual Virtual Global Healthcare Conference on September 9 at 2:45 PM ET. This event emphasizes Kaleido's innovative, chemistry-driven approach to microbiome health, focusing on developing Microbiome Metabolic Therapies (MMT™) to address significant patient needs. A webcast of the presentation will be available on their website, with an archived replay for 90 days post-event.

Kaleido Biosciences (Nasdaq: KLDO) reported a net loss of $23.9 million, or $0.56 per share, for Q2 2021, an increase from $18.9 million in Q2 2020. R&D expenses rose to $17.6 million due to increased clinical material production. The company plans to report topline data from a study of KB295 for ulcerative colitis by Q3 end and collaborate with the COPD Foundation on a Phase 2 study of KB109, targeting COPD patients in Q1 2022. Cash reserves stand at $72 million, with a runway into Q2 2022.